Rubix Life Sciences has announced an expansion and division aimed at some of the most high-growth therapeutic areas of pharma, including infectious diseases.
The CRO, which specializes in targeting minority and underserved populations, says it now plans to build a clinical trial site totaling up to 40,000 sq. ft. that will expand its Lawrence, Massachusetts facility. The new digs will also include a 10,000 sq. ft. fully automated digital experience care center for launching virtual clinical trials.
In 2016, Rubix LS founded a culturally centric life science research firm that aimed to build data, products, processes and programs to wholly support the clinical research continuum that includes minority data sets. The new expansion will enable the company to continue providing more support to the surrounding area — which is comprised of 80% Hispanic and Latino population — and facilitate research for under-represented populations. Both demographics comprise 18.7% of the U.S. population and account for more than half the country's growth. However, clinical representation dating back to 1983 to 2020 had less than 2.7% of their representation in research, making Rubix LS’ expansion critical. It is also expected to create 300 new jobs over the next three years.
In addition, the company said it has launched a new therapeutic division focused on diseases prevalent in underserved communities such as tropical, infectious, cardio, rare and neurodegenerative diseases.
